CRANBURY, N.J., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the `Company`), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into agreements with BioLexis Pte. Ltd. (`BioLexis`), its largest stockholder, and MTTR, LLC (`MTTR`), its development partner for ONS-5010, to better align the interests of all parties with the Company`s common stockholders and support the continued development of ONS-5010. `I want to thank the BioLexis and MTTR teams for working with the Company to restructure their arrangements with...
|